Literature DB >> 18499166

Late recurrence of symptomatic hydronephrosis in patients with prenatally detected hydronephrosis and spontaneous improvement.

Futoshi Matsui1, Kenji Shimada, Fumi Matsumoto, Shuichi Takano.   

Abstract

PURPOSE: Most prenatal hydronephrosis improves or resolves spontaneously with conservative treatment. However, late recurrence of prenatal hydronephrosis sometimes develops after improvement. To define the need for continuous observation after improvement of hydronephrosis, long-term followup was carried out in children with prenatally diagnosed hydronephrosis.
MATERIALS AND METHODS: We retrospectively evaluated 344 cases initially presenting between July 1991 and June 2004 with prenatally detected hydronephrosis that persisted postnatally. Subjects underwent periodic assessment of hydronephrosis using ultrasonography and diuretic renography. Indications for surgery were associated symptoms, enlarged renal pelvis, worsening hydronephrosis on sequential ultrasonography and decrease in differential renal function greater than 5%. Mean duration of followup was 10.1 years.
RESULTS: Of the 394 kidneys followed nonoperatively 4 (1%) displayed worsened hydronephrosis after spontaneous improvement. Initial grade of hydronephrosis was grade I in 1 patient, grade II in 1, grade III in 1 and grade IV in 1. On serial ultrasonographic followup hydronephrosis worsened to grade IV in 3 kidneys and to grade III in 1 kidney. Mean patient age at worsening of hydronephrosis was 40 months (range 22 to 60). All 4 patients presented with clinical symptoms. All patients who underwent pyeloplasty displayed no symptoms, and had improved hydronephrosis after pyeloplasty.
CONCLUSIONS: Prenatally detected hydronephrosis can worsen after spontaneous postnatal improvement. Long-term followup is not required after improvement of prenatal hydronephrosis. However, pediatric urologists need to tell the parents that the child should undergo ultrasonography if clinical symptoms develop.

Entities:  

Mesh:

Year:  2008        PMID: 18499166     DOI: 10.1016/j.juro.2008.03.065

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Canadian Urological Association/Pediatric Urologists of Canada guideline on the investigation and management of antenatally detected hydronephrosis.

Authors:  John-Paul Capolicchio; Luis H Braga; Konrad M Szymanski
Journal:  Can Urol Assoc J       Date:  2017-12-22       Impact factor: 1.862

Review 2.  Prenatal hydronephrosis: postnatal evaluation and management.

Authors:  Vijaya Vemulakonda; Jenny Yiee; Duncan T Wilcox
Journal:  Curr Urol Rep       Date:  2014-08       Impact factor: 3.092

Review 3.  Current management of antenatal hydronephrosis.

Authors:  Kleiton G R Yamaçake; Hiep T Nguyen
Journal:  Pediatr Nephrol       Date:  2012-07-27       Impact factor: 3.714

Review 4.  Ultrasonography of hydronephrosis in the newborn: a practical review.

Authors:  Young Hun Choi; Jung-Eun Cheon; Woo Sun Kim; In-One Kim
Journal:  Ultrasonography       Date:  2016-03-30

5.  Antenatally detected urinary tract dilatation: a 12-15-year follow-up.

Authors:  Maria Herthelius; Rimma Axelsson; Karl-Johan Lidefelt
Journal:  Pediatr Nephrol       Date:  2020-06-23       Impact factor: 3.714

6.  Asymptomatic obstructive hydronephrosis associated with diabetes insipidus: a case report and review.

Authors:  Long Sun; Dongyan Zhao; Linfeng Zhu; Yiding Shen; Yijun Zhao; Daxing Tang
Journal:  Transl Pediatr       Date:  2021-06

7.  Revised guidelines on management of antenatal hydronephrosis.

Authors:  A Sinha; A Bagga; A Krishna; M Bajpai; M Srinivas; R Uppal; I Agarwal
Journal:  Indian J Nephrol       Date:  2013-03

8.  Appropriate timing of performing abdominal ultrasonography and termination of follow-up observation for antenatal grade 1 or 2 hydronephrosis.

Authors:  Akihiro Nakane; Kentaro Mizuno; Taiki Kato; Hidenori Nishio; Hideyuki Kamisawa; Satoshi Kurokawa; Tetsuji Maruyama; Takahiro Yasui; Yutaro Hayashi
Journal:  BMC Urol       Date:  2020-11-03       Impact factor: 2.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.